Ortho Clinical Diagnostics now offers the VITROS^® SARS-CoV-2 antigen test on their VITROS® 3600, VITROS® 5600/ VITROS® XT7600 systems, designed to detect active infection, can be a vital additional supplement to current testing scenarios.

With utility for mass-scale testing and same-day results for labs, Ortho’s latest COVID-19 solution can run up to 130 tests per hour and immediately help hospitals and reference labs address testing backlogs, supply shortages, and delayed results. Thus, providing fast and accurate results.

Ortho’s COVID-19 antigen test was the first high-volume test to receive Food and Drug Administration (FDA) emergency use authorisation (EUA) in the US. In India, CDSCO also has given approval for emergency use.

“Even as vaccine inoculation programmes roll out, mass-scale testing remains an essential tool in fighting COVID-19. Ortho’s accurate, high-volume COVID-19 antigen test can play a pivotal role in the global response to this virus,” said Chris Smith, Chairman & CEO, Ortho Clinical Diagnostics.